Literature DB >> 9346923

The catalytic mechanism of mammalian adenylyl cyclase. Equilibrium binding and kinetic analysis of P-site inhibition.

C W Dessauer1, A G Gilman.   

Abstract

The mechanism of P-site inhibition of adenylyl cyclase has been probed by equilibrium binding measurements using 2'-[3H]deoxyadenosine, a P-site inhibitor, and by kinetic analysis of both the forward and reverse reactions (i.e. cyclic AMP and ATP synthesis, respectively). There is one binding site for 2'-deoxyadenosine per C1/C2 heterodimer; the Kd is 40 +/- 3 microM. Binding is observed only in the presence of one of the products of the adenylyl cyclase reaction, pyrophosphate (PPi). A substrate analog, Ap(CH2)pp (alpha,beta-methylene adenosine 5'-triphosphate), and cyclic AMP compete for the P-site in the presence of PPi, but P-site analogs do not compete for substrate binding (in the absence of PPi). Kinetic analysis indicates that release of products from the enzyme is random. These facts permit formulation of a model for the adenylyl cyclase reaction, for which we provide substantial kinetic support. We propose that P-site analogs act as dead-end inhibitors of product release, stabilizing an enzyme-product (E-PPi) complex by binding at the active site. Although product release is random, cyclic AMP dissociates from the enzyme preferentially. Release of PPi is slow and partially rate-limiting.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9346923     DOI: 10.1074/jbc.272.44.27787

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Molecular details of cAMP generation in mammalian cells: a tale of two systems.

Authors:  Margarita Kamenetsky; Sabine Middelhaufe; Erin M Bank; Lonny R Levin; Jochen Buck; Clemens Steegborn
Journal:  J Mol Biol       Date:  2006-07-28       Impact factor: 5.469

Review 2.  New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications.

Authors:  John Garthwaite
Journal:  Mol Cell Biochem       Date:  2009-12-11       Impact factor: 3.396

3.  Human recombinant soluble guanylyl cyclase: expression, purification, and regulation.

Authors:  Y C Lee; E Martin; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Structural analysis of adenylate cyclases from Trypanosoma brucei in their monomeric state.

Authors:  B Bieger; L O Essen
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

5.  Catalytic Mechanism of Mammalian Adenylyl Cyclase: A Computational Investigation.

Authors:  David K Hahn; Jose R Tusell; Stephen R Sprang; Xi Chu
Journal:  Biochemistry       Date:  2015-10-01       Impact factor: 3.162

6.  Assessment of cellular mechanisms contributing to cAMP compartmentalization in pulmonary microvascular endothelial cells.

Authors:  Wei P Feinstein; Bing Zhu; Silas J Leavesley; Sarah L Sayner; Thomas C Rich
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-23       Impact factor: 4.249

Review 7.  Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging.

Authors:  Stephen F Vatner; Misun Park; Lin Yan; Grace J Lee; Lo Lai; Kousaku Iwatsubo; Yoshihiro Ishikawa; Jeffrey Pessin; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-26       Impact factor: 4.733

8.  Pharmacological distinction between soluble and transmembrane adenylyl cyclases.

Authors:  Jacob L Bitterman; Lavoisier Ramos-Espiritu; Ana Diaz; Lonny R Levin; Jochen Buck
Journal:  J Pharmacol Exp Ther       Date:  2013-10-03       Impact factor: 4.030

9.  PAM mediates sustained inhibition of cAMP signaling by sphingosine-1-phosphate.

Authors:  Sandra C Pierre; Julia Häusler; Kerstin Birod; Gerd Geisslinger; Klaus Scholich
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

10.  Novel inhibitors of anthrax edema factor.

Authors:  Deliang Chen; Milind Misra; Laurie Sower; Johnny W Peterson; Glen E Kellogg; Catherine H Schein
Journal:  Bioorg Med Chem       Date:  2008-06-28       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.